Relapsed Pancreatoblastoma in Children: The Quest for Cure in This Rare Entity
Pancreatoblastoma constitutes the most common malignant pancreatic tumor in children. Pancreatoblastomas are rare and data to generate evidence-based management guidelines are limited. A literature review and pooled data analysis of cases 18 years old or younger with relapsed pancreatoblastoma (RP) was performed to describe their prognosis and management. The 2-year overall survival post-relapse (OS-pr) for patients with RP (n=15) was 54.4% (95% CI: 32.5%-71.6%). On the basis of surgery at relapse, the 2-year OS-pr was 85.7% (95% CI: 59.8%-96.1%) for cases who underwent surgery (n=9) versus 16.7% (95% CI: 1.1%-44.9%) for nonsurgical cases (n=6); P=0.003. This study shows that patients with RP can be salvaged and supports pursuing treatment with curative intent, including maximal safe resection where feasible.
Authors
- Nigel Heaton
- Fernando Carceller (ORCID: https://orcid.org/0000-0003-3094-3758)
- Stergios Zacharoulis
- Erika Pace (ORCID: https://orcid.org/0000-0002-5057-0154)
- Maesha Deheragoda
- Carlos Echecopar (ORCID: https://orcid.org/0000-0002-3916-4091)
Institutions
- Royal Marsden NHS Foundation Trust (GB)
- Institute of Cancer Research (GB)
- Columbia University Irving Medical Center (US)
- Hospital Universitario La Paz (ES)
- King's College Hospital (GB)
Publication Details
- Journal
- Journal of Pediatric Hematology/Oncology
- Published
- 2025-09-25
- DOI
- https://doi.org/10.1097/mph.0000000000003115
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00